We are live on ! Find out more
KBC Group

KBC Group Portfolio holdings

AUM $39.9B
1-Year Est. Return 29.7%
This Fund
S&P 500
This Quarter Est. Return
+0.55%
1 Year Est. Return
+29.7%
3 Year Est. Return
+99.77%
5 Year Est. Return
+133.11%
10 Year Est. Return
+496.57%
AUM
$10.8B
AUM Growth
-$884M
Cap. Flow
-$870M
Cap. Flow %
-8.04%
Top 10 Hldgs %
16.21%
Holding
1,353
New
94
Increased
424
Reduced
534
Closed
80

Top Buys

Rank Stock Value
1
CTSH icon
Cognizant
CTSH
+$36.9M
2
CAT icon
Caterpillar
CAT
+$35.6M
3
JPM icon
JPMorgan Chase
JPM
+$30.3M
4
SJM icon
J.M. Smucker
SJM
+$26.2M
5
INTC icon
Intel
INTC
+$24.6M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$58.6M
2
HPE icon
Hewlett Packard
HPE
+$42.2M
3
BABA icon
Alibaba
BABA
+$41.4M
4
TXN icon
Texas Instruments
TXN
+$35.2M
5
META icon
Meta Platforms (Facebook)
META
+$33.9M

Sector Composition

Rank Sector Weight
1 Technology 18.58%
2 Financials 18.08%
3 Healthcare 14.36%
4 Consumer Discretionary 11.3%
5 Industrials 10.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EPD icon
1251
Enterprise Products Partners
EPD
$83.7B
$20K ﹤0.01%
800
ESRT icon
1252
Empire State Realty Trust
ESRT
$1B
$18K ﹤0.01%
1,063
SHO icon
1253
Sunstone Hotel Investors
SHO
$2.19B
$18K ﹤0.01%
1,198
MNDT
1254
DELISTED
Mandiant, Inc. Common Stock
MNDT
$17K ﹤0.01%
+1,000
New +$16.1K
KRO icon
1255
KRONOS Worldwide
KRO
$712M
$16K ﹤0.01%
713
-184,298
-100% -$4.59M
LILA icon
1256
Liberty Latin America Class A
LILA
$1.72B
$16K ﹤0.01%
1,279
HRTX icon
1257
Heron Therapeutics
HRTX
$93.4M
$14K ﹤0.01%
500
ADVM
1258
DELISTED
Adverum Biotechnologies
ADVM
$13K ﹤0.01%
+220
New +$13.7K
IBA
1259
DELISTED
Industrias Bachoco SAB De C.V.
IBA
$12K ﹤0.01%
200
ADAP
1260
DELISTED
Adaptimmune Therapeutics
ADAP
$11K ﹤0.01%
950
MDXG icon
1261
MiMedx Group
MDXG
$630M
$11K ﹤0.01%
1,514
+1,000
+195% +$11.6K
NTLA icon
1262
Intellia Therapeutics
NTLA
$1.51B
$11K ﹤0.01%
525
BLCM
1263
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$11K ﹤0.01%
+161
New +$12.2K
FOLD
1264
DELISTED
Amicus Therapeutics
FOLD
$9K ﹤0.01%
620
NBIX icon
1265
Neurocrine Biosciences
NBIX
$18.2B
$9K ﹤0.01%
+110
New +$9.29K
SGMO
1266
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9K ﹤0.01%
450
AKAO
1267
DELISTED
Achaogen Inc
AKAO
$9K ﹤0.01%
+725
New +$8.23K
CPA icon
1268
Copa Holdings
CPA
$5.56B
$8K ﹤0.01%
59
-16,738
-100% -$2.24M
CYRX icon
1269
CryoPort
CYRX
$753M
$8K ﹤0.01%
950
THO icon
1270
Thor Industries
THO
$4.06B
$8K ﹤0.01%
+70
New +$9.35K
RDUS
1271
DELISTED
Radius Health, Inc.
RDUS
$8K ﹤0.01%
235
ZYNE
1272
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$6K ﹤0.01%
+650
New +$7.01K
CPL
1273
DELISTED
CPFL Energia S.A.
CPL
$6K ﹤0.01%
420
ADTN icon
1274
Adtran
ADTN
$675M
-68,741
Closed -$1.33M
AEIS icon
1275
Advanced Energy
AEIS
$10.1B
-6,529
Closed -$441K

Similar funds

KBC Group's Q1 2018 Portfolio in Review

As of Q1 2018, KBC Group held 1,353 positions worth $10.8B, down 7.6% from $11.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

KBC Group withdrew a net $870M in Q1 2018, closing 80 positions and reducing 534 holdings. Its most notable exit was Calgon Carbon Corp, an estimated $16.5M position sold in full.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

Against the trend, KBC Group opened a new position in Loxo Oncology, Inc worth $8.57M.

  • KBC Group's largest Q1 2018 buy was Loxo Oncology, Inc: 74,261 shares worth $8.57M.
  • KBC Group added most to Cognizant in Q1 2018, an estimated $36.9M increase.
  • KBC Group's biggest Q1 2018 reduction was Apple, cutting an estimated $58.6M.
  • KBC Group fully exited Calgon Carbon Corp in Q1 2018, selling an estimated $16.5M.
  • KBC Group's ten largest holdings make up 16% of its $10.8B portfolio in Q1 2018.
  • KBC Group opened 94 new positions and closed 80 in Q1 2018.
  • KBC Group's portfolio value fell 7.6% quarter-over-quarter to $10.8B.

Based on KBC Group's 13F filing for Q1 2018, filed 9 May 2018.